Agios Pharma (AGIO) Misses Q4 EPS by 15c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Agios Reports Fourth Quarter and Full Year 2017 Financial Results
February 14, 2018 7:01 AM ESTAll 2017 Key Milestones Achieved, Including First U.S. Product Approval from Agios Discovery Platform and NDA Submission for Second Product Candidate, Ivosidenib, for IDH1m R/R AML
2018 Priorities Focus on Expanding Clinical and Research Programs to Drive Long-Term Value
 2017 Year-End Cash, Cash Equivalents and Marketable Securities was $568M; January Follow-on Offering of $516M Extends Cash Runway Through at Least the End of 2020
CAMBRIDGE, Mass., Feb. 14, 2018 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the... More
